IMNMImmunome, Inc.
$19.56+108% 1Y
$19.56
$9.7752 weeks$29.84
The financials
Immunome, Inc. by the numbers
Immunome, Inc. (IMNM) reported revenue of $5.0M in Q2 2026 (quarter ended Jun 30, 2026), up 25% from the same quarter a year earlier. That came with net loss of $73M. For the full year FY2025, revenue was $6.9M (−23% year on year) and net income −$212M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $5.0M | $4.0M | +25% |
| Operating income | −$78M | −$46M | n/a |
| Net income | −$73M | −$43M | n/a |
| Diluted EPS | −$0.65 | −$0.50 | n/a |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2025Total $4.0M (+37%)
Single Reportable grew +70% year on year
Segment Latestquarter on quarteryear on year
- Single Reportable$4.0M$4.0Mquarter on quarter +37%year on year +70%+37%+70%
On our screens:Most shorted stocks